Commercial Manager, Mendelian
£45-55k
Commission
Accelerates diagnoses of rare diseases
Job no longer available
Accelerates diagnoses of rare diseases
21-100 employees
Job no longer available
£45-55k
Commission
21-100 employees
Company mission
We’re helping to end the diagnostic odyssey by bringing timely patient insights to primary care.
Jump to section
Company mission
We’re helping to end the diagnostic odyssey by bringing timely patient insights to primary care.
22% female employees
Our take
Rare diseases affect over 350 million patients worldwide. Unfortunately, it can take years of research and misdiagnoses before the correct rare disease is identified. This so-called "diagnostic odyssey" is not only causing patients distress and emotional turmoil, but also frustration among clinicians and an enormous financial burden on healthcare systems and associated trusts. This is the problem that Mendelian has set out to overturn.
Mendelian’s specialised screening system, dubbed MendelScreen, incorporates augmented intelligence and data analysis to produce a ranked list of likely causative disease genes based on how closely the patient’s query matches a disease. The company's platform is even more unique as it goes one step further to make "smart suggestions” regarding diagnosis, specialist referral and recommendations for further tests and analysis.
Mendelian's ultimate goal is to provide timely diagnoses for every patient suffering from a rare disease. It continually invests into its service to ensure the reports it provides are optimised for efficiency and data provision.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Pet-friendly office
- Work from home opportunities
- Meaningful equity package
Funding (last 2 of 5 rounds)
Mar 2023
$1.9m
GRANT
Feb 2022
$0.5m
GRANT
Total funding: $4.1m
This company has top investors
Leadership
Fran Garcia
(Chairman)Completed an MBA at INSEAD.
Rudy Benfredj
(CEO)Studied Computer Engineering at Imperial College London.